International Journal of Cell Biology chemosensitivity,” Cancer Research, vol. 65, no. 5, pp. 1961– 1972, 2005. [108] H. H. Zhang, A. I. Lipovsky, C. C. Dibble, M. Sahin, and B. D. Manning, “S6K1 regulates GSK3 under conditions of mTOR- dependent feedback inhibition of Akt,” Molecular Cell, vol. 24, no. 2, pp. 185–197, 2006. [109] M. Benkoussa, C. Brand, M. H. Delmotte, P. Formstecher, and P. Lefebvre, “Retinoic acid receptors inhibit AP1 activa- tion by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter,” Molecular and Cellular Biology, vol. 22, no. 13, pp. 4522–4534, 2002. [110] Y. Ma, Q. Feng, D. Sekula, J. A. Diehl, S. J. Freemantle, and E. Dmitrovsky, “Retinoid targeting of diﬀerent D- type cyclins through distinct chemopreventive mechanisms,” Cancer Research, vol. 65, no. 14, pp. 6476–6483, 2005. [111] J. Mori, F. Takahashi-Yanaga, Y. Miwa et al., “Diﬀerentiation- inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr286 in squamous cell carcinoma,” Experimental Cell Research, vol. 310, no. 2, pp. 426–433, 2005. [112] F. Takahashi-Yanaga, Y. Taba, Y. Miwa et al., “Dictyostelium diﬀerentiation-inducing factor-3 activates glycogen synthase kinase-3β and degrades cyclin D1 in mammalian cells,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9663– 9670, 2003. [113] M. Medina and J. Avila, “Glycogen synthase kinase-3 (GSK- 3) inhibitors for the treatment of Alzheimer’s disease,” Current Pharmaceutical Design, vol. 16, no. 25, pp. 2790– 2798, 2010. [114] J. Avila and F. Herna´ndez, “GSK-3 inhibitors for Alzheimer’s disease,” Expert Review of Neurotherapeutics, vol. 7, no. 11, pp. 1527–1533, 2007. [115] G. Klamer, E. Song, K. H. Ko, T. A. O’Brien, and A. Dolnikov, “Using small molecule GSK3β inhibitors to treat inﬂammation,” Current Medicinal Chemistry, vol. 17, no. 26, pp. 2873–2881, 2010. [116] S. Phukan, V. S. Babu, A. Kannoji, R. Hariharan, and V. N. Balaji, “GSK3β: role in therapeutic landscape and develop- ment of modulators,” British Journal of Pharmacology, vol. 160, no. 1, pp. 1–19, 2010. [117] W. J. Ryves, R. Dajani, L. Pearl, and A. J. Harwood, “Glyco- gen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites,” Biochemical and Biophysical Research Communications, vol. 290, no. 3, pp. 967–972, 2002. [118] A. Martinez, A. Castro, I. Dorronsoro, and M. Alonso, “Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inﬂammation,” Medicinal Research Reviews, vol. 22, no. 4, pp. 373–384, 2002. [119] M. Aoki, T. Yokota, I. Sugiura et al., “Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3β,” Acta Crystallographica D, vol. 60, no. 3, pp. 439–446, 2004. [120] B. Bax, P. S. Carter, C. Lewis et al., “The structure of phospho- rylated GSK-3β complexed with a peptide, FRATtide, that inhibits β-catenin phosphorylation,” Structure, vol. 9, no. 12, pp. 1143–1152, 2001. [121] J. A. Bertrand, S. Thieﬃne, A. Vulpetti et al., “Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors,” Journal of Molecular Biology, vol. 333, no. 2, pp. 393–407, 2003. [122] R. Bhat, Y. Xue, S. Berg et al., “Structural insights and biological eﬀects of glycogen synthase kinase 3-speciﬁc 11 inhibitor AR-A014418,” The Journal of Biological Chemistry, vol. 278, no. 46, pp. 45937–45945, 2003. [123] R. Dajani, E. Fraser, S. M. Roe et al., “Structural basis for recruitment of glycogen synthase kinase 3β to the axin-APC scaﬀold complex,” EMBO Journal, vol. 22, no. 3, pp. 494–501, 2003. [124] D. Shin, S. C. Lee, Y. S. Heo et al., “Design and synthesis of 7- hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3β,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 20, pp. 5686–5689, 2007. [125] H. C. Zhang, L. V. Bonaga, H. Ye, C. K. Derian, B. P. Dami- ano, and B. E. Maryanoﬀ, “Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glyco- gen synthase kinase-3,” Bioorganic & Medicinal Chemistry Letters , vol. 17, no. 10, pp. 2863–2868, 2007. [126] R. S. Jope, “Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes,” Trends in Pharmacological Sci- ences, vol. 24, no. 9, pp. 441–443, 2003. [127] M. P. Coghlan, A. A. Culbert, D. A. E. Cross et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription,” Chemistry and Biology, vol. 7, no. 10, pp. 793–803, 2000. [128] L. Meijer, A. M. W. H. Thunnissen, A. W. White et al., “Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent,” Chemistry and Biology, vol. 7, no. 1, pp. 51–63, 2000. [129] D. W. Zaharevitz, R. Gussio, M. Leost et al., “Discovery and initial characterization of the paullones, a novel class of smallmolecule inhibitors of cyclin-dependent kinases,” Cancer Research, vol. 59, no. 11, pp. 2566–2569, 1999. [130] R. Hoessel, S. Leclerc, J. A. Endicott et al., “Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases,” Nature Cell Biology, vol. 1, no. 1, pp. 60–67, 1999. [131] S. Leclerc, M. Garnier, R. Hoessel et al., “Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin- dependent kinase inhibitors?” Journal of Biological Chemistry, vol. 276, no. 1, pp. 251–260, 2001. [132] L. Meijer, A. L. Skaltsounis, P. Magiatis et al., “GSK-3- selective inhibitors derived from tyrian purple indirubins,” Chemistry and Biology, vol. 10, no. 12, pp. 1255–1266, 2003. [133] A. Martinez, M. Alonso, A. Castro, C. Pe´rez, and F. J. Moreno, “First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease,” Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1292–1299, 2002. [134] M. P. Coghlan, A. A. Culbert, D. A. E. Cross et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription,” Chemistry and Biology, vol. 7, no. 10, pp. 793–803, 2000. [135] G. M. Thomas, S. Frame, M. Goedert, I. Nathke, P. Polakis, and P. Cohen, “A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and β-catenin,” FEBS Letters, vol. 458, no. 2, pp. 247– 251, 1999.